Skip to main content
SpringerLink
Log in

Andere für das Prostata-Screening interessante Marker

  • Conference paper
Screening des Prostatakarzinoms

  • 18 Accesses

Zusammenfassung

Das Prostatakarzinom entwickelt sich schnell zum am häufigsten diagnostizierten Karzinom in der westlichen Welt [71], mit einer stetig wachsenden Inzidenzrate [24, 73] und einer bei der schwarzen Bevölkerung Amerikas doppelt so hohen Mortalitätsrate wie bei der weißen Bevölkerung. Darüber hinaus nimmt der Anteil der männlichen Bevölkerung jenseits des 65. Lj. insbesondere in Nordamerika und in den EG-Ländern weiterhin zu [24]. Prostataerkrankungen wie die benigne Prostatahypertrophie (BPH) oder das Prostatakarzinom werden in wachsendem Maße zu einem schwerwiegenden gesundheitspolitischen Problem. Daher ist es sicherlich an der Zeit, unsere Kenntnisse bezüglich des natürlichen Krankheitsverlaufs der BPH und des Prostatakarzinoms sowie der biologischen Vorgänge, die mit der Pathogenese dieser Krankheiten zusammenhängen, erneut zu überprüfen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adlercreutz H (1988) Lignans und phytoestrogens: possible preventive role in cancer. In: Rozen P, Horwitz C (eds) Frontiers in gastrointestinal research. Karger, Basle, pp 165–176

    Google Scholar 

  2. Atkin NB, Baker MC (1985) Chromosome study of five cancers of the prostate. Human Genetics 70:359–364

    Article  PubMed  CAS  Google Scholar 

  3. Atkin NB, Baker MC (1985) Chromosome 10 deletion in carcinoma of the prostate. New Engl J Medicine 312:315

    CAS  Google Scholar 

  4. Baba S (1982) Epidemiology of cancer of the prostate: analysis of countries of high and low incidence. In: Jacobi GH, Hohenfellner R (eds) Prostate cancer, international perspectives in urology, vol 3. Williams & Wilkins, Baltimore, pp 11–28

    Google Scholar 

  5. Baker SJ, Fearon ER, Nigro JM et al. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221

    Article  PubMed  CAS  Google Scholar 

  6. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912–915

    Article  PubMed  CAS  Google Scholar 

  7. Blute ML, Zincke H, Farrow GM (1986) Long-term follow up of young patients with stage A adenocarcinoma of the prostate. J Urol 136:840–843

    PubMed  CAS  Google Scholar 

  8. Bookstein Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee WH (1990) Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci 87:7762–7766

    Article  PubMed  CAS  Google Scholar 

  9. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH (1990) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712–715

    Article  PubMed  CAS  Google Scholar 

  10. Bostwick DG, Brawer MK (1987) Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 59:788–794

    Article  PubMed  CAS  Google Scholar 

  11. Bostwick DG (1989) Prostatic intraepithelial neoplasia (PIN). Urology 34 [Suppl]: 16–22

    PubMed  CAS  Google Scholar 

  12. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Blarney RW, Nicholson RI (1989) Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Brit J Cancer 59:943–947

    Article  PubMed  CAS  Google Scholar 

  13. Bravo R, Frank R, Blundell PA, MacDonald-Bravo H (1987) Cyclin/PCNA is the auxilliary protein of DNA polymerase delta. Nature (Lond) 326:515–520

    Article  CAS  Google Scholar 

  14. British Prostate Study Group (1979) Evaluation of plasma hormone concentrations in relation to clinical staging in patients with prostatic cancer. Brit J Urol 51:382–389

    Article  Google Scholar 

  15. Brothman AR, Peehl DM, Patel AM, McNeal JE (1990) Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res 50:3795–3803

    PubMed  CAS  Google Scholar 

  16. Brown DC, Cole D, Gaiter KC, Mason DY (1988) Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki-67. Brit J Cancer 57:178–181

    Article  PubMed  CAS  Google Scholar 

  17. Bussemakers MJG, Isaacs WB, Carter BS, van de Ven W, DeBruyne FMJ, Schalken JA (1991) E-cadherin is a candidate tumor suppressor gene implicated in prostate cancer. J Urol 145:294A

    Google Scholar 

  18. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA (1987) Enhanced expression of the c-myc protooncogene high-grade human prostate cancers. The Prostate 11:327–337

    Article  PubMed  CAS  Google Scholar 

  19. Buttyan R, Zakeri Z, Lockshin R, Wolgemuth D (1988) Cascade induction of c-fos, c-myc, and heat shock 70 K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol 2:650–657

    Article  PubMed  CAS  Google Scholar 

  20. Callahan R, Campbell G (1989) Mutations in human breast cancers: an overview. J Natl Cancer Inst 81:1780–1786

    Article  PubMed  CAS  Google Scholar 

  21. Cannon L, Bishop DT, Skolnick M, Hunt S, Lyon JL, Smart CR (1982) Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1:47–69

    Google Scholar 

  22. Cantrell BB, deKlerk DP, Eggleston JC, Boitnott JK, Walsh PC (1981) Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol 125:516–520

    PubMed  CAS  Google Scholar 

  23. Carter BS, Ewing CM, Ward SW et al. (1990) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci 87:8751–8755

    Article  PubMed  CAS  Google Scholar 

  24. Carter HB, Coffey DS (1988) Prostate cancer: the magnitude of the problem in the United States. In: Coffey DS, Resnick MI, Dorr FA, Karr JP (eds) A multidisciplinary analysis of controversies in the management of prostatic cancer. Plenum Press, New York, pp 1–7

    Chapter  Google Scholar 

  25. Cooke DB, Quarmby VE, Mickey DD, Isaacs JT, French FS (1988) Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostate adenocarcinoma system. The Prostate 13:263–272

    Article  PubMed  CAS  Google Scholar 

  26. Curran T, Bravo R, Muller R (1985) Transient induction of c-fos and c-myc is an immediate consequence of growth factor stimulation. Cancer Surv 4:655–681

    PubMed  CAS  Google Scholar 

  27. Ekman P (1989) BPH epidemiology and risk factors. The Prostate 2 [Suppl]:23–31

    CAS  Google Scholar 

  28. Epstein JI, Pauli G, Eggleston JC, Walsh PC (1986) Prognosis of untreated stage A prostate carcinoma: a study of 94 cases with extended follow-up. J Urol 136:837–839

    PubMed  CAS  Google Scholar 

  29. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Dodd JG, Mutusik RJ (1986) Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46:1535–1538

    PubMed  CAS  Google Scholar 

  30. Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H (1984) Growth fractions in malignant non-Hodgkin’s lymphomas as determined in situ with the monoclonal antibody Ki-67. Haematol Oncol 2:365–371

    CAS  Google Scholar 

  31. Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Reps 50:125–128

    CAS  Google Scholar 

  32. Golimbu M, Schinella R, Morales P, Kurusu S (1978) Differences in pathological characteristics and prognosis of clinical Al and B disease. J Urol 119:618–622

    PubMed  CAS  Google Scholar 

  33. Griffiths K, Davies P, Eaton CL, Harper ME et al. (1987) In: Clark JR (ed) Oxford Reviews of Reproductive Biology, vol 9. Oxford University Press, pp 192–259

    Google Scholar 

  34. Griffiths K, Davies P, Eaton CL, Harper ME, Turkes A, Peeling WB (1991) In: Voigt KD, Knabbe C (eds) Endocrine dependent tumors. Raven, New York, pp 83–130

    Google Scholar 

  35. Haenzel W, Kurihara M (1968) Studies of Japanese migrants. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40:43–68

    Google Scholar 

  36. Harper ME, Glynne-Jones E, Goddard L et al. (1992) Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. The Prostate 20

    Google Scholar 

  37. Harper ME, Goddard L, Wilson DW, Matenhelia SS, Conn IG, Peeling WB, Griffiths K (1992) Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. The Prostate 21:75–84

    Article  PubMed  CAS  Google Scholar 

  38. Harper ME, Wilson DW, Jensen HM, Pierrepoint CG, Griffiths K (1987) Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade. J Steroid Biochem 27:521–524

    Article  PubMed  CAS  Google Scholar 

  39. Helpap B (1989) Do precursor lesions of prostatic carcinoma exist? World J Urol 7:27–33

    Article  Google Scholar 

  40. Huang H-J, Yee J-K, Shew J-Y et al. (1988) Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563–1566

    Article  PubMed  CAS  Google Scholar 

  41. Isaacs JT, Coffey DS (1989) Etiology and disease process of benign prostatic hyperplasia. The Prostate, Suppl 2:33–50

    CAS  Google Scholar 

  42. Jain S, Filipe MI, Hall PA, Waseem NH, Lane DA, Levison DA (1991) Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Path 44:655–659

    Article  PubMed  CAS  Google Scholar 

  43. Kastendieck H (1980) Correlations between atypical primary hyperplasia and carcinoma of the prostate. Pathol Res Pract 169:366–387

    Article  PubMed  CAS  Google Scholar 

  44. Katz AE, Benson MC, Wise GJ et al. (1989) Gene activity during the early phase of androgen-stimulated rat prostate regrowth. Cancer Res 49:5889–5894

    PubMed  CAS  Google Scholar 

  45. Klein G (1987) The approaching era of the tumor suppressor genes. Science 238:1539–1545

    Article  PubMed  CAS  Google Scholar 

  46. Knudson AG (1985) Hereditary cancer, oncogenes and anti-oncogenes. Cancer Res 45:1437–1443

    PubMed  CAS  Google Scholar 

  47. Koppe IM, Heranze DR, Shimkin MB (1967) Characteristics of patients with prostatic carcinoma: a control case study on 83 autopsy pairs. J Urol 98:229–233

    Google Scholar 

  48. Kovi J, Mostofi FK (1989) Atypical hyperplasia of prostate. Urology 34 [Suppl]:23–27

    PubMed  CAS  Google Scholar 

  49. Krain LS (1974) Some epidemiologic variables in prostatic carcinoma in California. Preventive Medicine 3:154–159

    Article  PubMed  CAS  Google Scholar 

  50. Lee WH, Bookstein R, Lee EY-HP (1988) Studies on the human retinoblastoma susceptibility gene. J Cellular Biochem 38:213–227

    Article  CAS  Google Scholar 

  51. Marx JL (1987) The fos gene as master switch. Science 237:854–856

    Article  PubMed  CAS  Google Scholar 

  52. McNeal JE, Bostwick DG (1986) Intraductal dysplasia: A premalignant lesion of the prostate. Human Pathol 17:64–71

    Article  CAS  Google Scholar 

  53. McNeal JE (1978) Origin and evolution of benign prostatic enlargement. Invest Urol 15:340–345

    PubMed  CAS  Google Scholar 

  54. McNeal JE (1981) The zonal anatomy of the prostate. The Prostate 2:35–49

    Article  PubMed  CAS  Google Scholar 

  55. McNeal JE (1975) Structure and pathology of the prostate. In: Goland M (ed) Normal and abnormal growth of the prostate. Thomas, Springfield, pp 55–65

    Google Scholar 

  56. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA (1986) Patterns of progression in prostate cancer. Lancet 1:60–63

    Article  PubMed  CAS  Google Scholar 

  57. McNeal JE, Price HM, Redwine EA, Freiha FS, Stamey TA (1988) Stage A versus stage B adenocarcinoma of the prostate: morphologic comparison and biologic significance. J Urol 139:61–65

    PubMed  CAS  Google Scholar 

  58. Meikle AW, Smith JA, West DW (1985) Familial factors affecting prostatic cancer risk and plasma sex steroid levels. The Prostate 6:121–128

    Article  PubMed  CAS  Google Scholar 

  59. Miller JG (1988) Diagnosis of stage A prostate cancer in the People’s Republic of China. In: Coffey DS, Resnick MI, Dorr FA, Karr JP (eds) A multidisciplinary analysis of controversies in the management of prostate cancer. Plenum Press, New York, pp 17–24

    Chapter  Google Scholar 

  60. Morganti G, Gianferrari L, Cresseri A, Arrigoni G, Lovati G (1956) Récherches clinico-statistiques et génétiques sur les néoplasies de la prostate. Acta Genetica Statistica 6:304–305

    Google Scholar 

  61. Mostofi FK, Sesterhehn I, Sobin LH (1980) Histological typing of prostatic tumours. International histological classification of tumours, No 22. Geneva, World Health Organisation

    Google Scholar 

  62. Natt E, Magenis RE, Zimmer J, Mansouri A, Scherer G (1989) Regional assignment of the human loci for uvomorulin and chymotrypsinogen B with the help of two overlapping deletions on the long arm of chromosome 16. Cytogenetics and Cell Genetics 50:145–148

    Article  PubMed  CAS  Google Scholar 

  63. Oomens EHGM, van Steenbrugge GJ, van der Kwast TH, Schroeder FH (1991) Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the proliferative cell fraction of human prostatic carcinoma. J Urol 145:81–85

    PubMed  CAS  Google Scholar 

  64. Oota K, Misu Y (1958) A study of latent carcinoma of the prostate in Japanese. Gann 49:283–293

    Google Scholar 

  65. Partin AW, Isaacs JT, Treiger G, Coffey DS (1988) Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with v-Harvey-ras oncogene. Cancer Res 48:6050–6053

    PubMed  CAS  Google Scholar 

  66. Peehl DM, Wehner N, Stamey TA (1987) Activated Ki-ras oncogene in human prostatic adenocarcinoma. The Prostate 10:281–289

    Article  PubMed  CAS  Google Scholar 

  67. Phillips MEA, Ferro MA, Smith PJB, Davies P (1987) Intranuclear androgen receptor deployment and protogene expression in human diseased prostate. Urol Int 42:115–119

    Article  PubMed  CAS  Google Scholar 

  68. Rich AR (1935) On frequency of occurrence of occult carcinoma of prostate. J Urol 33:215–223

    Google Scholar 

  69. Rijnders AWM, van der Korput JAGM, van Steenbrugge GJ, Romijn JC, Trapman J (1985) Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 132:548–554

    Article  PubMed  CAS  Google Scholar 

  70. Sager R (1989) Tumor suppressor genes: the puzzle and the promise. Science 246:1406–1412

    Article  PubMed  CAS  Google Scholar 

  71. Silverberg E, Lubera JA (1989) Cancer Statistics. Cancer 39:3–20

    CAS  Google Scholar 

  72. Skeet RG (1976) Epidemiology of urological tumours. In: Williams DI, Chisholm GD (eds) Scientific foundations of urology, vol IL Heinemann, London, pp 199–211

    Google Scholar 

  73. Sondik E (1988) Incidence, survival and mortality trends in prostate cancer in the United States. In: Coffey DS, Resnick MI, Dorr FA, Karr JP (eds) A multidisciplinary analysis of controversies in the management of prostatic cancer. Plenum Press, New York, pp 9–16

    Chapter  Google Scholar 

  74. Stamey TA (1982) Cancer of the prostate. In: Stamey TA (ed) Monographs in urology 3:1–10

    Google Scholar 

  75. Steinberg GS, Carter BS, Beaty TH, Childs B, Walsh PC (1990) Family history and the risk of prostate cancer. The Prostate 17:337–347

    Article  PubMed  CAS  Google Scholar 

  76. Thompson TC, Southgate J, Kitchner G, Land H (1989) Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56:917–930

    Article  PubMed  CAS  Google Scholar 

  77. Treiger B, Isaacs JT (1988) Expression of a v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. J Urol 140:1580–1586

    PubMed  CAS  Google Scholar 

  78. Tsai Y, Nichols P, Hiti A, Williams Z, Skinner D, Jones P (1990) Allelic losses of chromosomes 9, 11 and 17 in human bladder cancer. Cancer Res 50:44–47

    PubMed  CAS  Google Scholar 

  79. Turkes A, Nott JP, Griffiths K (1991) Prostate-specific antigen: problems in analysis. Eur J Cancer 27:650–652

    Article  PubMed  CAS  Google Scholar 

  80. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R (1989) Allelotype of colorectal cancinomas. Science 244:207–211

    Article  PubMed  CAS  Google Scholar 

  81. Weinberg RA (1989) Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49:3713–3721

    PubMed  CAS  Google Scholar 

  82. Weisz A, Bresciani F (1988) Estrogen induces expression of c-fos and c-myc protoonco-genes in rat uterus. Molecular Endocrin 2:816–824

    Article  CAS  Google Scholar 

  83. Weisz A, Rosales R (1990) Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Research 18:5097–5106

    Article  PubMed  CAS  Google Scholar 

  84. Weisz A, Cicatiello L, Persico E, Scalona M, Bresciani F (1990) Estrogen stimulates transcription of c-jun protooncogene. Molecular Endocrin 4:1041–1050

    Article  CAS  Google Scholar 

  85. Whitmore WF (1986) Stage A prostatatic cancer. J Urol 136:883

    PubMed  Google Scholar 

  86. Woolf CM (1960) An investigation of the familial aspects of carcinoma of the prostate. Cancer 13:739–744

    Article  PubMed  CAS  Google Scholar 

  87. Wynder EL, Mabuchi K, Whitmore WF (1971) Epidemiology of cancer of the prostate. Cancer 28:344–360

    Article  PubMed  CAS  Google Scholar 

  88. Yokota J, Wada M, Shimosato Y, Terado M, Sigimura T (1987) Loss of heterozygosity on chromosome 3, 13 and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci 84:9252–9256

    Article  PubMed  CAS  Google Scholar 

  89. Yu CC-W, Hall PA, Fletcher CDH, Camplejohn R, Waseem NH, Lane DP, Levison DA (1990) Immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen may be a good predictor of prognosis in haemangiopericytomas. J Path 161:342a

    Google Scholar 

  90. Yunis Y (1983) Chromosomal basis of neoplasia. Science 221:335–340

    Article  Google Scholar 

Download references

Authors
  1. M. E. Harper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. L. Eaton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Turkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Griffiths
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Abteilung, Klinikum Memmingen, Bismarckstraße 23, D-87700, Memmingen, Deutschland

    Peter Faul

  2. Urologische Abteilung, Krankenhaus der Barmherzigen Brüder, Romanstraße 93, D-80639, München, Deutschland

    Jens E. Altwein

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Harper, M.E., Eaton, C.L., Turkes, A., Griffiths, K. (1995). Andere für das Prostata-Screening interessante Marker. In: Faul, P., Altwein, J.E. (eds) Screening des Prostatakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78318-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78318-0_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78319-7

  • Online ISBN: 978-3-642-78318-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation